Dear Friends,

In this issue of the newsletter, our VP of scientific operations, Hollie Schmidt, shares some highlights from the 2017 Annual American Academy of Neurology Conference held in Boston. She focuses on three key topics of particular interest to many with MS: disease-modifying therapies (DMTs), risk factors, and comparative effectiveness.

We’re pleased to bring you our third article from epidemiologist Farren Briggs, Asking When Do MS Symptoms Start?, Farren walks us through the framework of the natural course of a disease such as MS and looks into a Canadian study that explored the topic of a pre-clinical stage of MS by analyzing the health care records of more than 86,000 people (including 14,428 with MS).

We also are profiling four longtime supporters of ACP. Each has supported ACP for many years donating their time and raising money to sustain ACP's mission. We are very grateful for their support. Can we help you bring a fundraising idea into reality?

**Highlights from the 2017 AAN Annual Meeting**

The American Academy of Neurology (AAN) annual meeting is one of the top conferences for people who study and treat MS. ACP representatives have attended this meeting annually since 2003. Since this year’s meeting was in our backyard (Boston), several of us took the opportunity to attend, joining over 10,000 neurology professionals from across the world.

The MS-related presentations and classes spanned a variety of topics, from pregnancy in MS, to new imaging techniques, to diagnosis, and so on. Below are summaries of the presentations we found particularly interesting, mostly on the topics of MS medications (disease-modifying therapies) and risk factors for MS. If you’d like to learn more or explore other topics, the meeting abstracts are available for everyone to browse. Just go to this link – [http://submissions.mirasmart.com/AAN2017/itinerary/SearchHome.asp](http://submissions.mirasmart.com/AAN2017/itinerary/SearchHome.asp) – and search for the topics that interest you.
Disease-modifying therapies (DMTs):

Ludwig Kappos reviewed the positive results of the Phase III study of Novartis’s oral drug siponimod in SPMS, which were first presented at ECTRIMS last fall. Siponimod is a similar compound to fingolimod (Gilenya®). The conclusion is that siponimod works to decrease disease progression and looks promising as a treatment for SPMS.

Another set of results were presented by Peter Calabresi on a Phase II study of opicinumab. This Biogen drug blocks a factor (LINGO-1) that interferes with remyelination. Four doses were tested in people with relapsing-remitting or secondary progressive MS who were simultaneously treated with interferon-beta (Avonex®). Interestingly, the people on the two middle doses had better outcomes than those on the highest or lowest doses. The outcomes seen in the study fell short of what was hoped for. However, Biogen saw enough signs of promise to continue, and will use what they learned about people who did well on the drug to design future studies of opicinumab.

One of the panels featured drugs that were very early in the development process. David Weinstein reviewed data from a study of CHS-131, a drug that is similar to the diabetes medicine pioglitazone but tweaked to have fewer side effects. A small study in MS showed a reduction of inflammatory lesions and brain atrophy (shrinkage) compared with placebo. No safety problems were detected, so the company developing CHS-131 (Coherus) is proceeding with further study of a higher dose. Also, a research program at the University of California San Francisco that screens drugs for their remyelination potential found that the drug bazedoxifene shows promise. This drug is a selective estrogen receptor modulator under development for postmenopausal osteoporosis.

While many presentations describe treatments that are not yet on the market, there is still much to be learned about the long-term performance of available DMTs. Douglas Arnold provided results from people who enrolled in the CARE-MS I alemtuzumab study. These participants received alemtuzumab upon joining the study and 12 months later, and have since been followed for 6 years. Over the follow-up period, 66% had no new or enlarged MRI lesions, and 63% needed no further treatment.

One of the main conference sessions, called “Controversies in Neurology,” included a debate about whether DMTs should be discontinued in people with progressive MS. John Corboy argued in favor of stopping DMTs upon evidence of progression. He stated that in clinical trials with people with MS whose age is < 40 years, the DMTs have demonstrated a benefit on a variety of standard outcome measures. However, for those above 40 years old, the DMTs have not demonstrated benefit on standard outcome measures. He proposed discontinuation and medical monitoring. Robert Naismith, taking the other side of the argument, conceded some of Dr. Corboy’s points but said that there were still opportunities for people with progressive MS to derive benefit from treatment with DMTs. For example, certain clinical trials have shown benefits for upper extremity function, cognition and vision. He focused also on “What does the patient want?” It was concluded that a formal study was needed.
Risk factors:

Vitamin D deficiency has been associated with a higher risk of developing MS, which begs the question of whether vitamin D supplementation can help reduce disease activity in people already diagnosed with MS. William Camu and Joost Smolders described two similar European studies comparing the combination of interferon beta (Rebif®) with vitamin D3 to interferon beta alone in people with MS. The studies showed some reductions in relapses and MRI activity among people taking vitamin D. However, most of these results were not statistically significant, likely due to the small numbers of participants and high percentage of dropouts. For instance, in Dr. Camu’s study, 24% of the placebo recipients stopped taking Rebif partway through the study due to relapses, so they could not participate for the full 2 years.

Another set of presentations dealt with the topic of viral infections as risk factors for MS. Annette Langer-Gould presented data from a Southern California population showing some differences in antibodies to Epstein Barr virus (EBV) and cytomegalovirus (CMV) in Caucasians, African-Americans and Hispanics. A similar study of patients at 16 MS pediatric centers found a strong association between MS and past EBV infection in all racial and ethnic groups. In this study, the MS patients had higher vitamin D levels than controls, probably because children with MS are more likely to receive vitamin D supplements than other kids.

Noriko Isobe reviewed what we know to date about the genetics of MS and to assess whether genetic data could someday be used to guide MS healthcare. So far over 230 gene variants have been found to affect the risk of MS. Dr. Isobe and colleagues determined the “genetic burden” of people with MS and controls by seeing how many of these MS risk variants they have. They found that men have a higher genetic burden than women; that having more variants in a specific region with immune-related genes was associated with younger age of onset and brain atrophy in women with RRMS; and that people with a single MS symptom tend to have additional disease activity faster if their genetic burden is high.

Sunali Goonesekera gave a presentation on the worldwide prevalence of MS. Estimates range from less than 1 in 10,000 in Africa and the Middle East to more than 1.3 in 1,000 in Europe and North America. Substantial increases in prevalence are predicted in Asian, Middle East and Africa, in part because of improvements in diagnosis. RRMS is the most common type of MS worldwide, and there is little variation in the distribution of subtypes despite differences in prevalence.

Finally, Michael Levy described the discovery of a rare genetic variant (VPS37A) and its association with a familial form of transverse myelitis. He and his team identified the gene
variant in 2 sisters, one who developed TM at age 15 and the other who developed symptoms at age 50. The Hopkins group then used ACP Repository biosamples to find one new familial TM patient with the same gene variant. The gene codes for a protein involved in a cellular recycling system that is associated with other neurodegenerative diseases.

**Comparative effectiveness:**

Perhaps the biggest puzzle facing neurologists and people with MS today is determining which MS drug will work the best for a given person. To partially solve this puzzle, a number of “comparative effectiveness” studies have been conducted or are underway which compare two or three drugs on a set of outcomes.

One of the poster sessions featured these types of studies. We’ve summarized a few of the research topics to show the type of research being done in this area and the range of outcomes being evaluated:

- Fingolimod (Gilenya®) and interferon beta-1a (Avonex®) compared on a blood biomarker (neurofilament light chain)
- Fingolimod and glatiramer acetate (Copaxone®) compared on brain volume changes
- Dimethyl fumarate (Tecfidera®), fingolimod and teriflunomide (Aubagio®) compared on risk of relapse
- Peginterferon beta-1a (Plegridy®) and teriflunomide compared on disability worsening and relapse rate
- Fingolimod, interferons, and glatiramer acetate compared on treatment satisfaction

While these comparisons are interesting, they can’t tell an individual person with MS which of the treatments being compared would be better for them based on their own individual characteristics and preferences. ACP is working on a “personalized medicine” approach to generate that type of evidence. We hope to be able to present findings from this work at an upcoming AAN conference!

**Overall impressions:**

25 years ago, neurologists had very few “tools” to treat neurological disorders: epilepsy drugs, drugs for Parkinsons symptoms, some migraine and pain drugs, and a few others. Now there are medications for some of the formerly untreatable neurological conditions, with multiple MS DMTs leading the way. New treatments for spinal muscular atrophy and advances in stroke treatment provide brighter outlooks for the very young and not-so-young alike. The past 25 years have seen a transformation of neurology from the old adage “Diagnose and Adios.” The coming years promise a lot for people with neurological conditions and brain injury. We look forward to continuing to move the MS field forward with our colleagues from around the world.
When do MS symptoms start?
By Farren Briggs PhD, ScM

For MS epidemiologists, we are interested in identifying factors influencing the natural history (progression/severity) of MS. Alternatively stated: determining factors contributing to the manifestation of MS. And defining manifestation is where things get really interesting. What is the appropriate definition: Is disease activity measured by number of relapses? Or is time between relapses more relevant? What about the rate of disability, such time from onset to using a walking cane? How about the diversity in symptoms and the patterns of symptoms? Well, these are all important interpretations of the term. But to study the manifestation of MS, we must start at the beginning.

I teach an introductory class on epidemiology, and in one of my first lectures I introduce a conceptual framework of the natural course of a disease. Figure 1 is a hypothetical timeline of the natural history of a chronic disease with a genetic and environmental/lifestyle risk component; such as in MS.

![Figure 1: Natural history timeline of a chronic disease.](image)

In studying the natural history of MS, and resultant MS progression, we should start at the beginning of the disease. But when does the disease start? For most of us, researchers or not, we generally conceptualize the start of MS as the first episode of neurological dysfunction (the first clinically noticeable symptom). However, as shown in Figure 1 there is the subclinical stage, where MS disease processes are ongoing but there has been no clinical event, therefore pre-clinical MS goes undetected. For some diseases, screening tests can be used to detect the disease while in the subclinical stage (i.e. mammography to detect breast cancer before symptoms even start). Developing screening tests for MS is an active research area, but in the meantime, are there other subtle symptoms and signs occurring during the subclinical stage to aid in detecting MS earlier?

This month in *Lancet Neurology*, a Canadian research team reports there is a pre-clinical phase in MS⁴. The study used health administration records from four Canadian provinces (British

---

Columbia, Saskatchewan, Manitoba, and Nova Scotia). Due to the nature of the Canadian health-care system, these provinces have computerized health-care records on >99% of residents, including hospital discharges, physician billing, prescription records, and dates of all medical visits – all records can be linked by a unique health-care number assigned to individuals. Using these records, medical histories for 14,428 MS cases and 72,059 controls were included for this study. They compared health-care utilization in the same five years period prior MS diagnosis between cases and temporally matched controls. Interestingly, five years before a MS diagnosis, the number of hospital admissions for people who eventually developed MS was 26% higher than controls, and this increased to 78% higher a year before MS diagnosis. A similar pattern was observed for physician billing (5 years before diagnosis: 24% higher in people with MS than controls; 1 year before diagnosis: 88% higher in people with MS than controls). There was also a substantial increase in the number of prescribed drug classes in people with MS compared to controls (5 years before diagnosis: 23% higher; 1 year before diagnosis: 49% higher). These results clearly demonstrate a pre-clinical stage for MS where subtle symptoms exist before clinically definitive symptoms (also known as a prodromal stage). With further research, we can explore these subtle symptoms and hopefully diagnose MS earlier and initiate therapeutics earlier, slowing the rate of progression of MS.
Raising Awareness and Funds for ACP

The work that ACP does to accelerate research into MS is supported in part by donations, large and small. We are very grateful to fundraisers Patrick and Erin Curley, Nancy and Judy Medeiros, Rick Szczepanski and Freda Warrington for their recent (and ongoing!) support of our mission. They are all raising awareness and funds for ACP.

On Saturday, May 6th sisters Nancy and Judy Medeiros held their 15th Annual Sports Scholarship Benet in loving memory of their brother, Edmund J. Medeiros. The evening is something friends and family look forward to every year, as it is a night to remember Edmund, support ACP, and to enjoy a delicious dinner, great music, and a wonderful raffle. It was another successful year for the Medeiros family. ACP is thankful for their 15 years of support.

Patrick and Erin Curley participated in the Essex River Race on Saturday, May 20th. They each kayaked the 6-mile race through the rough water and they have the blisters to show for it! They raised over $6,000 for ACP, and they're looking forward to doing the event again next year! Thank you, Patrick and Erin for going the extra mile for ACP!

Rick Szczepanski runs the Mary J. Szczepanski "Never Give Up" MS Scholarship Foundation, created in 1997 to honor his mother who fought multiple sclerosis for 38 years, and now his wife who was diagnosed with MS over 26 years ago. The foundation offers 10 annual scholarship opportunities for all US high school seniors and college students who raise funds for Accelerated Cure Project.

Finishing their 17th year, the national high school recipients from across the country ranging from Michigan to Louisiana raised over $2000 for ACP! All three recipients will be awarded $1,000 for college tuition. To learn more about the scholarship visit www.msscholarship.org.

Longtime ACP supporter and friend, Freda Warrington has written a wonderful book, “Listen to the Light: Stories of Interruptions, Intersections and Insights”. Proceeds from the sale of the book will benefit MS research, including ACP. Why not buy the book for yourself or as a gift? We can’t wait for books 2 and 3!

Have an idea for a fundraiser to support ACP? We would be delighted to speak with you and to turn your idea into reality! Please email or call Lindsey at lsantiago@acceleratedcure.org or 781.487.0013.
**MS Minority Research**

Accelerated Cure Project is interested in making sure that MS research benefits everyone. We have formed the [MS Minority Research Engagement Partnership Network](#) to understand how people with MS from different backgrounds and races think about medical research. The MS Minority Research Engagement Partnership Network is made up of [people with multiple sclerosis, doctors, and other health leaders](#).

We want to understand how people with MS from different backgrounds and races think about participating in medical research. What do you think is important to study? What would help you be a part of the study?

If you are at least 21 years old and have multiple sclerosis, we invite you to complete a [survey](#) and share your thoughts on MS medical research. The survey should take around 15 minutes to complete. Everyone is invited!

[Take the Survey](#)

[Conteste la Encuesta](#)

*Newsletter in part sponsored by:*

![Biogen](#)

![TEVA Pharmaceuticals](#)